I am quoting below from that NY Post article:
"Only two other dolls made it onto Panjiva’s top 10 list: Mattel’s Monster High dolls, a line featuring teen goth characters inspired by monster movies and books, which comes in at No. 3 with 828 shipments; and Jakks Pacific’s Sofia the First doll, the title character in Disney’s new animated Disney series about a girl princess, at No. 7 with 364 shipments."
My post does not go through if I put that link. Search for keywords from above quote in google to get the link to the artcile
I feel it will unfortunately go much lower over coming days. But it will come back up at some point.
From the BIND article on YHOO: “Up to this point, biological barriers present in the human body, such as the intestinal epithelial lining, the blood brain barrier, and the mucosa of the lungs and eyes, have hindered absorption of nanoparticles. By targeting the neonatal Fc receptor, our founders have demonstrated the ability to successfully engineer targeted therapeutic nanoparticles that cross biological barriers and enter the bloodstream at therapeutic levels, which we believe could pave the road for opportunities for Accurin therapeutics for a myriad of other biological applications"
New target by end of first quarter and this should be much higher than 15 by then
OK maybe my memory regarding buyout of Avanir was bad. Teva was showing interest. However, the person neurologist Devanand Jillapalli MD, who reviewed Zenvia is same as for this one. His one line final regulatory recommendation in that one was same as this one. - I recommend approval
Same FDA reviewer recommended that Zenvia be approved. That was more complicated situation than this one. FDA approved the drug. Later Avanir Pharma was bought by TEVA.
From forbes article and agree with it this time
Arrowhead Research Corp. (ARWR) looked exceptional on Wednesday. It’s one of our swing trades, which popped on Tuesday to our target and backed off. It went all the way down to 6.00 on Wednesday, exploded to 7.35, and closed at 7.23, up 41 cents, or 6% on 1.4 million shares. Nice reversal. Decent volume. If it punches up through Tuesday’s high at 7.53, it may very well get up to the 9-9 1/2 range.